ClinicalTrials.gg
Not yet recruitingNCT07877805Updated Oct 16, 2026

Merlin Expanded ECG NSR

An observational study in Heart Failure and Bradycardia, sponsored by Abbott Medical Devices. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Abbott Medical Devices (part of Abbott) · Observational

Updated Oct 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 120 studies in Heart Failure by Abbott — 6 open to participants now, 9 under way, none of them phase 3. Heart Failure · Abbott.

Planned enrollment
32nd of 45
50 · median 154
Started
2026
the only one that year
Observational
45 of 120
4 open now
Registered
120th of 120
by date

Among the 120 studies in Heart Failure by Abbott, this one is the 32nd largest by planned enrollment of the 45 observational ones that give a count, is the only one that started in 2026, is one of 45 observational ones, and was the 120th registered.

Heart Failure

6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

6 of the 120 studies in Heart Failure by Abbott are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Heart Failure by Abbott, or all of them as a file.
02

Study summary

This clinical investigation is a prospective, single-arm, multi-center, observational study designed to evaluate the concordance between a simplified electrocardiogram (ECG) method implemented on the Merlin™ 3650 or MER3700 programmer and the standard 12-lead ECG during left bundle branch area pacing (LBBAP) in patients with a bradycardia indication for pacemaker implantation. The study will enroll approximately 50 subjects across up to 5 U.S. sites, with data collected during the implant procedure, and optionally post-implant at the pre-discharge evaluation. No post-discharge follow-up is planned.

03

Conditions studied

  • Heart Failure
  • Bradycardia

Keywords

  • Left Bundle Branch area pacing
  • ECG
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects must meet all general eligibility criteria and provide written informed consent prior to sites conducting any investigation-specific procedures not considered standard of care.

This intended population for this clinical investigation is adult patients (≥18 years) who are scheduled to undergo pacemaker implantation with left bundle branch area pacing (LBBAP) for the treatment of heart failure or bradycardia. Subjects must meet all eligibility criteria and provide written informed consent prior to any clinical investigation-specific procedures not considered standard of care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must provide written prior to any clinical investigation-related procedure.
  2. Subject is at least 18 years of age.
  3. Subject is scheduled to undergo a standard low-voltage lead implant in the left bundle branch area for either bradycardia or heart failure per the site's standard of care.

Exclusion criteria

Exclusion Criteria:

  1. Subject is currently participating in another clinical investigation that may impact study outcomes, as determined by the study sponsor or lead investigator.
  2. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period.
  3. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation results.

    Protocol-Specific Screening Exclusion Criteria (if applicable)

  4. Subject has a mechanical tricuspid valve, percutaneous tricuspid valve repair or replacement, or an implanted vena cava filter.
  5. Subject has evidence of tricuspid stenosis, tricuspid atresia, or any condition that precludes appropriate vascular access for the procedure.
  6. Subject has an existing lead or device in the right heart or interventricular septum (including lead fragments and closure devices).
  7. Subject has known allergy or to \<1 mg of dexamethasone sodium phosphate or any blood/tissue-contacting material used in the procedure.
  8. Subject is unable to receive heparin or an acceptable alternative for anticoagulation.
  9. Subject has an active systemic infection.
  10. Subject has known history or repair of atrial septal defect, patent foramen ovale, or ventricular septal defect.
  11. Subject is unable to read or write
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Enrollment Group

    Enrollment group will undergo a standard low-voltage lead implant in the left bundle branch area for either bradycardia or heart failure per the site's standard of care. Enrollment group will undergo data collection from different ECG methods.

    Device: Left Bundle Branch Implant

Interventions

  • DeviceLeft Bundle Branch Implant

    Standard of care for left bundle branch implant will be used in the study.

06

What researchers measure

Primary outcomes

  1. Concordance rate for LBBAP capture assessment between ECG recordings

    Concordance rate for LBBAP capture assessment between different ECG recordings

    Time frame: Periprocedural

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Results of the trial will be shared but individua participant data will not be released.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jan 2027, 3 months later.

Of 183 industry-sponsored observational studies under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 57. This study's planned 3 months is below that.

Counting every sponsor, half of 981 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2026
First posted
Oct 16, 2026
StartEst.
Oct 5, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Mar 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07877805
Responsible party
Sponsor
First posted
Oct 16, 2026
Start date
Oct 5, 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Clinical Project Manager
Contact
pooja.maddula@abbott.com
+1 818-282-2302
Clinical Scientist
Contact
eric.johnson10@abbott.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion